Blurbs

Analysts Conflicted on These Healthcare Names: Replimune Group (REPL), Minerva Surgical (UTRS) and Nektar Therapeutics (NKTR)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Replimune Group (REPLResearch Report), Minerva Surgical (UTRSResearch Report) and Nektar Therapeutics (NKTRResearch Report).

Replimune Group (REPL)

J.P. Morgan analyst Anupam Rama maintained a Buy rating on Replimune Group on August 26 and set a price target of $33.00. The company’s shares closed last Friday at $19.17.

According to TipRanks.com, Rama is a 3-star analyst with an average return of 1.6% and a 44.9% success rate. Rama covers the Healthcare sector, focusing on stocks such as Day One Biopharmaceuticals, Springworks Therapeutics, and Apellis Pharmaceuticals.

Currently, the analyst consensus on Replimune Group is a Strong Buy with an average price target of $43.25, implying a 108.6% upside from current levels. In a report issued on August 16, Piper Sandler also maintained a Buy rating on the stock with a $43.00 price target.

See the top stocks recommended by analysts >>

Minerva Surgical (UTRS)

J.P. Morgan analyst Robbie Marcus upgraded Minerva Surgical to Buy yesterday. The company’s shares closed last Friday at $1.77, close to its 52-week low of $1.61.

According to TipRanks.com, Marcus is a 4-star analyst with an average return of 6.9% and a 45.7% success rate. Marcus covers the Healthcare sector, focusing on stocks such as Bausch + Lomb Corporation, Zimmer Biomet Holdings, and Baxter International.

Minerva Surgical has an analyst consensus of Moderate Buy, with a price target consensus of $5.00.

Nektar Therapeutics (NKTR)

Nektar Therapeutics received a Hold rating from J.P. Morgan analyst Jessica Fye yesterday. The company’s shares closed last Friday at $4.38, close to its 52-week low of $3.02.

According to TipRanks.com, Fye is a 4-star analyst with an average return of 8.2% and a 51.2% success rate. Fye covers the Healthcare sector, focusing on stocks such as Cerevel Therapeutics Holdings, Crinetics Pharmaceuticals, and Intra-Cellular Therapies.

Nektar Therapeutics has an analyst consensus of Hold, with a price target consensus of $4.93.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on REPL:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos